FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W808863290> ?p ?o ?g. }

• W808863290 abstract "Abstract Eph receptors are the largest subgroup of the receptor tyrosine kinases (RTK). Unlike other RTK, these function principally during development. Quiescent in postembryonic tissues, Eph expression by adult tissues is abnormal and implicated in tumor initiation, invasion and metastasis. Aberrant EphA3 expression is seen in solid and hematologic tumors, particularly advanced stage lymphoproliferative and myeloproliferative diseases. In this regard, targeting EphA3 may constitute a novel treatment for hematological malignancy. With clinical utility in mind, i.e., patient selection for anti-EphA3 therapy, a panel of commercial and proprietary (KaloBios) antibodies was screened by Western Blot for reactivity to recombinant Eph receptors (EphA3, EphA4, EphA5, EphA7, EphB2, EphB3). Those with EphA3 binding selectivity were further screened (QualTek) by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) normal and diseased human bone marrow (NLBM, AML) as well the LK63 pre-B-ALL cell line from which EphA3 was originally isolated. Different tissue pretreatments were used for antigen/epitope retrieval of EphA3, including steam-heating in citrate-based or Tris & chelator-based buffers, subsequent/or protease digestion, or neither. Following each antigen/epitope retrieval procedure, antibody reactivity for EphA3 was assessed by light microscopy using enzymatic biotin, tyramide and polymer-based detection techniques. In each instance, the location of the EphA3/antibody complex was visualized with 3,3-diaminobenzidine that precipitates a discrete insoluble reaction product in presence of enzyme (HRP). Nuclei were counterstained with hematoxylin to assess cell/tissue morphology. From this screen, one antibody (with an epitope in the cytoplasmic CT-domain of EphA3) was chosen for further assay optimization based on its selective reactivity towards LK63 and AML and low selective reactivity towards NLBM. Assay optimization included, amongst other aspects, evaluation of EphA3 expression in a panel of NLBM and hematopoietic tumors (200+ specimens inclusive of acute & chronic leukemia, peripheral T-cell & B-cell neoplasm, Hodgkin & non-Hodgkin lymphoma, multiple myeloma, myelodysplasic syndrome, myeloproliferative neoplasm) by a board-certified hematopathologist. In NLBM, the frequency of EphA3+ immature-blast cells (CD34+ or CD117+) was insignificant. Less than 10% CD34+/CD117+ cells were EphA3+. Elevated EphA3 expression (percentage EphA3+ nucleated cells) was observed in most hematopoietic tumors. For example, in multiple myeloma, tumor cells were typically EphA3+/CD138+ plasma cells. For AML, leukemic CD34+ or CD117+ blasts/initiating cells were typically EphA3+. Some CD138- plasma cells or leukemic CD34-/CD117- cells were also EphA3+. Correlation was made between EphA3 expression and specific tumor maturation stages, differentiation status and/or tumor aggressiveness. Tumors in blast crisis presented elevated EphA3 expression, e.g., CML in accelerated or blastic crisis but not chronic phase. Elevated EphA3 expression was noted in pre-B-ALL & pro-B-ALL (early pre-B-ALL) rather than mature B-cell ALL. EphA3 expression for some peripheral B-cell neoplasms correlated well with tumor grade: high grade, poorly differentiated (typically aggressive) B-cell lymphomas or follicular lymphomas were EphA3+. A similar relationship was noted for non-Hodgkin lymphoma (Hodgkin lymphoma was EphA3-). Preclinical screening also provided evidence for EphA3 expression by stroma/fibroblast (mostly lymphoma) and vasculature/endothelium, further rationale for development of reliable tools for profiling EphA3 in hematologic tumors and other malignancies. Using well-characterized normal and diseased FFPE bone marrow biopsies, this IHC assay for EphA3 has subsequently been validated (QualTek) to provide data that is not directly available from routine histopathology review and that supports use of the assay for profiling EphA3 in specific hematologic tumors and for patient selection in early Phase clinical trial/s of an anti-EphA3 monoclonal antibody (KB004, KaloBios). Beyond this, EphA3 targeted therapy with KB004 is anticipated for treatment of solid tumors. Recent genome-wide surveys identify EphA3 amongst the most frequently overexpressed genes in pancreatic, colon and lung carcinoma, melanoma and glioblastoma. Disclosures: Locke: QualTek Molecular Labs: Employment. Bernstein:QualTek Molecular Laboratories: Employment, Equity Ownership. Lynch:QualTek Molecular Laboratories: Employment, Equity Ownership. Siami-Namini:QualTek Molecular Laboratories: Consultancy. Walling:KaloBios: Consultancy; Corcept Therapeutics: Consultancy; Prothena: Consultancy; New Gen Therapeutics: Consultancy; Valent Technologies: Consultancy; LBC Pharmaceuticals: Consultancy; Amgen: Equity Ownership; BioMarin: Equity Ownership; Crown BioScience: Membership on an entity’s Board of Directors or advisory committees. Yonker:KaloBios: Employment, Equity Ownership. Yarranton:KaloBios: Employment, Equity Ownership; Glaxo: Equity Ownership; EnGen: Equity Ownership, Science Advisor, Science Advisor Other; StemLine Therapeutics: Equity Ownership." @default.
• W808863290 created "2016-06-24" @default.
• W808863290 creator A5003709231 @default.
• W808863290 creator A5007259776 @default.
• W808863290 creator A5037185733 @default.
• W808863290 creator A5076273559 @default.
• W808863290 creator A5079216280 @default.
• W808863290 creator A5085711583 @default.
• W808863290 date "2013-11-15" @default.
• W808863290 modified "2023-09-27" @default.
• W808863290 title "An IHC Screen For EphA3 Positive FFPE Tumors" @default.
• W808863290 doi "https://doi.org/10.1182/blood.v122.21.4965.4965" @default.
• W808863290 hasPublicationYear "2013" @default.
• W808863290 type Work @default.
• W808863290 sameAs 808863290 @default.
• W808863290 citedByCount "0" @default.
• W808863290 crossrefType "journal-article" @default.
• W808863290 hasAuthorship W808863290A5003709231 @default.
• W808863290 hasAuthorship W808863290A5007259776 @default.
• W808863290 hasAuthorship W808863290A5037185733 @default.
• W808863290 hasAuthorship W808863290A5076273559 @default.
• W808863290 hasAuthorship W808863290A5079216280 @default.
• W808863290 hasAuthorship W808863290A5085711583 @default.
• W808863290 hasConcept C101544691 @default.
• W808863290 hasConcept C104317684 @default.
• W808863290 hasConcept C142724271 @default.
• W808863290 hasConcept C147483822 @default.
• W808863290 hasConcept C153911025 @default.
• W808863290 hasConcept C159654299 @default.
• W808863290 hasConcept C170493617 @default.
• W808863290 hasConcept C185592680 @default.
• W808863290 hasConcept C19331615 @default.
• W808863290 hasConcept C195616568 @default.
• W808863290 hasConcept C203014093 @default.
• W808863290 hasConcept C204232928 @default.
• W808863290 hasConcept C2776415932 @default.
• W808863290 hasConcept C2779484032 @default.
• W808863290 hasConcept C502942594 @default.
• W808863290 hasConcept C55493867 @default.
• W808863290 hasConcept C71924100 @default.
• W808863290 hasConcept C86803240 @default.
• W808863290 hasConceptScore W808863290C101544691 @default.
• W808863290 hasConceptScore W808863290C104317684 @default.
• W808863290 hasConceptScore W808863290C142724271 @default.
• W808863290 hasConceptScore W808863290C147483822 @default.
• W808863290 hasConceptScore W808863290C153911025 @default.
• W808863290 hasConceptScore W808863290C159654299 @default.
• W808863290 hasConceptScore W808863290C170493617 @default.
• W808863290 hasConceptScore W808863290C185592680 @default.
• W808863290 hasConceptScore W808863290C19331615 @default.
• W808863290 hasConceptScore W808863290C195616568 @default.
• W808863290 hasConceptScore W808863290C203014093 @default.
• W808863290 hasConceptScore W808863290C204232928 @default.
• W808863290 hasConceptScore W808863290C2776415932 @default.
• W808863290 hasConceptScore W808863290C2779484032 @default.
• W808863290 hasConceptScore W808863290C502942594 @default.
• W808863290 hasConceptScore W808863290C55493867 @default.
• W808863290 hasConceptScore W808863290C71924100 @default.
• W808863290 hasConceptScore W808863290C86803240 @default.
• W808863290 hasLocation W8088632901 @default.
• W808863290 hasOpenAccess W808863290 @default.
• W808863290 hasPrimaryLocation W8088632901 @default.
• W808863290 hasRelatedWork W1965412973 @default.
• W808863290 hasRelatedWork W2032520688 @default.
• W808863290 hasRelatedWork W2033112544 @default.
• W808863290 hasRelatedWork W2057986081 @default.
• W808863290 hasRelatedWork W2095036378 @default.
• W808863290 hasRelatedWork W2154207271 @default.
• W808863290 hasRelatedWork W2155366350 @default.
• W808863290 hasRelatedWork W2565004846 @default.
• W808863290 hasRelatedWork W2622655612 @default.
• W808863290 hasRelatedWork W2909015925 @default.
• W808863290 hasRelatedWork W2988188154 @default.
• W808863290 hasRelatedWork W2995606934 @default.
• W808863290 hasRelatedWork W3083491539 @default.
• W808863290 hasRelatedWork W3136153275 @default.
• W808863290 hasRelatedWork W3171091793 @default.
• W808863290 hasRelatedWork W3211785432 @default.
• W808863290 hasRelatedWork W132149998 @default.
• W808863290 hasRelatedWork W2225930746 @default.
• W808863290 hasRelatedWork W2836559987 @default.
• W808863290 hasRelatedWork W2924060889 @default.
• W808863290 isParatext "false" @default.
• W808863290 isRetracted "false" @default.
• W808863290 magId "808863290" @default.
• W808863290 workType "article" @default.